Application of trigonelline in preparation of medicine for preventing or treating prostatic hyperplasia

Abstract

The invention discloses application of trigonelline in preparation of a medicine for preventing or treating prostatic hyperplasia. A rat benign prostatic hyperplasia (BPH) model is established through a testosterone propionate induction method, and a method of histology and molecular biology is adopted to verify that the trigonelline can significantly reduce the prostate wet weight and reduce the prostate index; the prostatic hyperplasia is observed to be obviously relieved in form; the PSA level in serum is obviously reduced; and it shows that the trigonelline has an improvement effect on BPH of rats and can be used for preparing the medicine for preventing or treating the prostatic hyperplasia.

Description

technical field

[0001] The invention relates to the technical field of drug application, in particular to the application of trigonelline in the preparation of drugs for preventing or treating benign prostatic hyperplasia. Background technique

[0002] BPH generally refers to benign prostatic hyperplasia. Benign prostatic hyperplasia (BPH) is a common progressive disease in middle-aged and elderly men. Due to the increasingly prominent problem of population aging, the incidence of BPH has increased significantly. Studies have found that the incidence of BPH in men over 50 years old is about 50%, and that of men over 80 years old is as high as 90%. As the excessive enlargement of prostate tissue further leads to bladder outlet obstruction, about 50% of men over 60 years old show different symptoms. Degree of clinical symptoms, such as urinary frequency, urgency, urinary weakness, urinary retention or occasional urge incontinence secondary to bladder detrusor hypersensitivit...

Images